Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Common Stock Repurchased

Cash spent buying back the company's own shares.

Novo Nordisk A/SNYSE: NVO

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased turns negative

Q2 FY2026 common stock repurchased was -DKK 3.5B, compared with DKK 0 a year earlier. Trailing-twelve-month common stock repurchased was -DKK 5.9B. Over 3 fiscal years it compounded at -61.4% a year.

Context

  • Common stock repurchased amounted to 0.4% of revenue in FY2025, down 6.5 pp from a year earlier.
  • Common stock repurchased grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near -DKK 3.5B or moves back toward the trailing-twelve-month quarterly average of -DKK 1.47B.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-DKK 3.5B+45.8% QoQ
Last fiscal yearDec 2025
-DKK 1.39B-93.1% YoY
LTMJun 2026
-DKK 5.9B-47.7% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-93.1%——
3-year CAGR-61.4%——
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

DKK · from the cash flow

Latest · FY2025
(1.39B) DKK
Year-over-year change
+93.1%

Common Stock Repurchased vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.7% is the lowest of 8, against a peer median of +40.5%.
  • Common stock repurchased amounts to 1.8% of revenue for NVO, versus a peer median of 2.5%.
NVO Competitors
Common Stock Repurchased for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
JNJJohnson & JohnsonLTM Sep 2026$7.88B USD+82.8%-0.5%7.9%
LLYEli Lilly and CompanyLTM Jun 2026$6.17B USD+40.5%+39.9%7.7%
NVONovo Nordisk A/SLTM Jun 2026DKK 5.9B DKK-47.7%-61.4%1.8%
MRKMerck & Co., Inc.LTM Jun 2026$4.21B USD+22.2%—6.3%
ABBVAbbVie Inc.LTM Jun 2026$1.51B USD+11.6%-13.0%2.3%
SNYSanofiLTM Jun 2026€1.21B EUR—+125.2%2.5%
GSKGSK plcLTM Jun 2026£1.08B GBP+34.0%—3.3%
AZNAstraZeneca PLCLTM Sep 2026$348.8M USD+2624.7%—0.6%
AMGNAmgen Inc.LTM Jun 2026$0 USD+100.0%—0.0%
PFEPfizer Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding NVO) —+40.5%+19.7%2.5%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.